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In Brief
Curran et al. demonstrate that, in contrast
to solid cancers, a host type I IFN
response is not triggered in leukemia-
bearing hosts. However, induction of type
I IFN and other inflammatory cytokines
through STING pathway activation results
in potent leukemia-specific immunity,
culminating in prolonged survival of mice
with AML.
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Type I interferon (IFN), essential for spontaneous
T cell priming against solid tumors, is generated
through recognition of tumor DNA by STING. Inter-
estingly, we observe that type I IFN is not elicited in
animals with disseminated acute myeloid leukemia
(AML). Further, survival of leukemia-bearing animals
is not diminished in the absence of type I IFN
signaling, suggesting that STING may not be trig-
gered by AML. However, the STING agonist, DMXAA,
induces expression of IFN-b and other inflammatory
cytokines, promotes dendritic cell (DC) maturation,
and results in the striking expansion of leukemia-
specific T cells. Systemic DMXAA administration
significantly extends survival in two AML models.
The therapeutic effect of DMXAA is only partially
dependent on host type I IFN signaling, suggesting
that other cytokines are important. A synthetic cyclic
dinucleotide that also activates human STING pro-
vided a similar anti-leukemic effect. These data
demonstrate that STING is a promising immunother-
apeutic target in AML.
INTRODUCTION
Anti-tumor T cell responses develop spontaneously in a fraction
of cancer patients and the presence of tumor-infiltrating T cells
has prognostic implications (Galon et al., 2006; Page`s et al.,
2005; Mahmoud et al., 2011; Hwang et al., 2012). How the sterile
tumor environment supports tumor-specific T cell priming has
been of significant interest in recent years. Gene expression
profiling of human melanomas has revealed a type I interferon
(IFN) signature in tumors heavily infiltrated by CD8+ T cells (Ga-
jewski, 2007), suggesting that type I IFN might be important for
bridging innate and adaptive anti-tumor immune responses.
Direct evidence in support of this hypothesis has come from an-
imal models in which type I IFN signaling in host cells was neces-
sary to promote spontaneous anti-tumor CD8+ T cell priming
(Fuertes et al., 2011; Diamond et al., 2011). Furthermore, severalCe
This is an open access article undgroups have demonstrated that transplanted and carcinogen-
induced solid tumors grow more rapidly in type I IFN receptor-
deficient (Ifnar/) mice (Dunn et al., 2005; Fuertes et al.,
2011). Collectively, these observations have established an
essential role for type I IFN in generating adaptive immune
responses against solid cancers.
The cancer cell-derived signals that induce host type I IFN
production remained elusive until it was shown that tumor DNA
triggered IFN-b production by dendritic cells (DCs) in vivo
through activating the cytosolic DNA-sensing stimulator of IFN
genes (STING) pathway (Woo et al., 2014). In the native STING
pathway, cyclic dinucleotides known as cyclic GMP-AMPs
(cGAMPs) are generated from cytosolic DNA by the enzyme
cGAMP synthase (cGAS) (Sun et al., 2013; Wu et al., 2013).
Upon cGAMP binding, the STING homodimer undergoes a
significant conformational change and traffics from the endo-
plasmic reticulum to the Golgi, where it recruits tank-binding
kinase 1 (TBK1), resulting in its phosphorylation, activation of
IFN regulatory factor 3 (IRF3), and transcription of type I IFN (Ish-
ikawa and Barber, 2008; Ishikawa et al., 2009). STING also acti-
vates the STAT6 and necrosis factor kappa B (NF-kB) pathways,
inducing the expression of a number of inflammatory cytokines
and chemokines, including CCL20, tumor necrosis factor alpha
(TNF-a), and interleukin-6 (IL-6) (Sun et al., 2013; Wu et al.,
2013; Chen et al., 2011; Fu et al., 2015).
Recent work indicates that, in the setting of a localized tumor,
spontaneous anti-tumor CD8+ T cell responses are abrogated in
STING-deficient hosts, but they occur normally in mice deficient
in other nucleic acid-sensing receptors (Woo et al., 2014), sug-
gesting that tumor-derived DNA and STING are critical for gener-
ating adaptive anti-tumor immunity. However, in contrast to solid
malignancies, hematological cancers, such as acute myeloid
leukemia (AML), are typically disseminated at inception and
lack classical draining lymph nodes. While it has been demon-
strated that AML cells can be recognized by the host immune
system (Ohminami et al., 2000), the mechanisms that regulate
immunity and immune tolerance against this disease and, specif-
ically, the roles of STING and type I IFN are relatively unknown.
Interestingly, our recent work has implicated antigen-presenting
cells (APCs), producers of type I IFN, in generating a unique
T cell-tolerant state in AML-bearing animals (Zhang et al.,
2013), suggesting that the host type I IFN response may not bell Reports 15, 2357–2366, June 14, 2016 ª 2016 The Authors 2357
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Systemic AML Fails to Induce a
Host Type I IFN Response
(A) C1498 cells (53 106) were inoculated i.v. or s.c.
into C57BL/6 mice. Control mice received PBS i.v.
Three days later, ifnb expression in bulk spleen
cells (i.v. C1498 or PBS mice) or in draining lymph
node cells (s.c. C1498 mice) was analyzed by
qRT-PCR and normalized to controls that received
PBS i.v. Data are pooled from three independent
experiments each with three mice per group and
represented as mean ± SEM.
(B) C57BL/6 and Ifnar/ mice were challenged
with 106 C1498 cells i.v. and survival was
assessed.
(C) C57BL/6 and Ifnar/mice received 106 C1498
cells s.c. and tumor volume was assessed over
time. Data are pooled from two independent ex-
periments, each with four to five mice per group,
and represented as mean ± SEM.
n.s., not significant; **p < 0.01 and ***p < 0.001.activated in this disease. If this is the case, strategies aimed at
stimulating type I IFN production in AML-bearing hosts, such
as through STING activation, might lead to effective adaptive
immunity against leukemia-derived antigens.
Here we demonstrate that a host type I IFN response is not
generated in mice with systemic AML. Further, the survival of
leukemia-bearing mice is similar in the presence or absence
of host type I IFN signaling and STING, in sharp contrast to
what has been observed in solid tumor models (Fuertes et al.,
2011; Diamond et al., 2011; Woo et al., 2014). However, admin-
istration of the STING agonist 5,6-demethylxanthenone-4-ace-
tic acid (DMXAA) to animals with established AML induces
type I IFN and TNF-a production, leads to APC maturation,
and culminates in extremely potent activation of leukemia
antigen-specific CD8+ T cells. DMXAA treatment significantly
prolongs the survival of and, in some cases, cures mice with
AML. Collectively, these results provide strong rationale for
the therapeutic development of STING agonists as immuno-
therapy for AML.
RESULTS
Disseminated AML Fails to Induce a Host Type I IFN
Response
Host type I IFN signaling is necessary for the generation of spon-
taneous CD8+ T cell responses against solid tumors (Fuertes
et al., 2011; Diamond et al., 2011). To determine whether type I
IFN was induced in mice with systemic leukemia, C1498 AML
cells were inoculated intravenously (i.v.) into C57BL/6 mice and
Ifnb expression was measured in bulk spleen cells. Ifnb expres-
sion also was analyzed in the tumor-draining lymph nodes
(TDLNs) of mice given a localized (subcutaneous [s.c.]) C1498
challenge as a positive control (Fuertes et al., 2011). Ifnb
mRNA levels were similarly low in spleen cells from leukemia-
free and i.v. C1498 cell-challenged animals. In contrast, Ifnb
expression could be readily detected in TDLN cells from s.c.2358 Cell Reports 15, 2357–2366, June 14, 2016C1498 cell-challenged mice, as expected (Figure 1A). To deter-
mine whether type I IFN signaling was important for the genera-
tion of functional immune responses to systemic AML, survival of
wild-type and Ifnar/ mice given an i.v. challenge with C1498
cells was compared, and it was found to be quite similar (Fig-
ure 1B). Conversely, and in agreement with published data, tu-
mors derived from s.c.-implanted C1498 cells progressed
more rapidly in Ifnar/ compared to wild-type mice (Figure 1C).
Collectively, these results indicate that a disseminated leukemia
fails to stimulate a type I IFN response in the host.
The STING Agonist DMXAA Induces IFN-b, TNF-a, and
IL-6 Expression In Vivo
Various STING agonists, including synthetic cyclic dinucleotides
(CDNs) and DMXAA, have been used therapeutically with suc-
cess, either when injected intra-tumorally or when administered
as part of a localized cancer vaccine (Corrales et al., 2015; Fu
et al., 2015). Because IFN-bwas not induced in animals with sys-
temic AML, it was of interest to determine if a systemically deliv-
ered STING agonist could generate a host type I IFN response
sufficient to mediate control or rejection of AML. Following i.v.
administration, DMXAA induced Ifnb expression in spleen cells
in a STING-dependent manner, as demonstrated by lack of
Ifnb expression in DMXAA-treated Tmem173/ (STING-defi-
cient) mice (Figure S1A). STING also activates NF-kB through a
poorly understood mechanism. Consistent with this, enhanced
Tnfa and Il6 expression levels were observed in the spleens
of DMXAA-treated mice, also in a STING-dependent manner
(Figures S1B and S1C). Serum levels of IFN-b, TNF-a, and
IL-6 also were elevated following DMXAA treatment (Figures
S1D–S1F).
DMXAA Treatment Activates Host APCs
Type I IFN has been shown to directly activate APCs (Mon-
toya et al., 2002). Because DMXAA administration induced
type I IFN, an in vivo effect on DCs and macrophages was
next investigated through an analysis of their cell surface
expression of co-stimulatory and major histocompatibility com-
plex (MHC) class II molecules, as well as IL-12 production.
Increased expression of CD80, CD86, and MHC class II was
observed on DCs and, to a lesser extent, on macrophages
from DMXAA-treated animals, again in a STING-dependent
manner (Figures S2A and S2B). Furthermore, IL-12 production
was 2- to 3-fold higher in DCs following DMXAA treatment.
Macrophages did not produce any detectable IL-12 at base-
line or following STING activation (Figures S2C and S2D).
Collectively, these data demonstrate that DMXAA treatment
activates APCs, and DCs in particular, which may enhance
their capability to stimulate adaptive anti-leukemia immune
responses.
STING Activation Stimulates Potent Leukemia-Specific
CD8+ T Cell Responses
Having shown that DMXAA treatment induces type I IFN expres-
sion and APC activation, its effect on leukemia-specific CD8+
T cell responses was next investigated. C57BL/6 mice were
challenged i.v. with C1498.SIY cells, and subsequently they
were treated with DMXAA or vehicle control. 1 week later,
endogenous SIY-specific CD8+ T cell responses were analyzed
in the spleen and bone marrow of leukemia-bearing animals.
As shown in Figures 2A–2C, a striking expansion of SIY-specific
CD8+ T cells occurred in DMXAA- versus vehicle control-treated
mice. Importantly, the effect of DMXAA on the expansion of SIY-
specific T cells required their exposure to cognate antigen, as no
increase in the frequency or number of antigen-specific CD8+
T cells occurred in DMXAA-treated, leukemia-free animals (Fig-
ures 2A–2C). Antigen-specific CD8+ T cells in DMXAA-treated,
leukemia-bearing animals were functional and produced IFN-g
following ex vivo re-stimulation (Figures 2D and 2E). In contrast,
very few IFN-g+ CD8+ T cells were generated in vehicle control-
treated mice with AML (Figures 2D and 2E). Also important was
the observation that DMXAA did not induce IFN-g production by
polyclonal CD8+ T cells in naive mice (Figures 2D and 2E). The
effect of DMXAA on enhanced leukemia-specific CD8+ T cell
priming was completely STING dependent, and it did not occur
in leukemia-bearing Tmem173/ hosts treated with DMXAA
(data not shown). These data demonstrate that STING activation
promotes the robust expansion of endogenous leukemia anti-
gen-specific T cells.
To directly track the proliferation and expansion of AML-
specific CD8+ T cells following STING activation, T cell receptor
(TCR) transgenic (Tg) CD8+ 2C T cells, which specifically recog-
nize the SIY antigen, were CTV labeled and adoptively trans-
ferred into C57BL/6 mice. C1498.SIY AML cells were then inoc-
ulated i.v. and DMXAA or vehicle control was administered. In
leukemia-free mice, 2C T cells remained largely undivided,
whether or not DMXAA was administered, indicating that STING
activation did not stimulate leukemia-specific T cells in the
absence of antigen (Figures S3A and S3B). The 2C T cells prolif-
erated but failed to expand significantly in leukemia-bearing
mice treated with vehicle control, as we have reported previously
(Figures S3A and S3B) (Zhang et al., 2013). Interestingly, DMXAA
treatment led to the accumulation of large numbers of fully
divided 2C T cells in leukemia-bearing animals (Figures S3Aand S3B). The frequency of 2C T cells isolated fromAML-bearing
mice that produced IFN-g also was enhanced following DMXAA
treatment (Figures S3C and S3D). As shown in Figure S3E, the
amount of IFN-g produced on a per-cell basis was also higher
in 2C T cells from DMXAA- versus vehicle control-treated mice
with AML. Together, these data demonstrate that activation of
the STING pathway leads to an impressive expansion of func-
tional leukemia-specific CD8+ T cells following adoptive transfer
into mice with established AML.
To confirm that DMXAA-induced STING activation did not
cause antigen-independent CD8+ T cell expansion in vivo, 2C
and OT-1 T cells (the latter of which recognizes an irrelevant an-
tigen derived from chicken ovalbumin) were co-transferred into
mice. The following day, mice received C1498.SIY cells i.v. or re-
mained leukemia-free. DMXAA or vehicle control was adminis-
tered, and the frequencies of 2C and OT-1 T cells subsequently
were analyzed. OT-1 T cells failed to expand in any group,
regardless of AML cell inoculation or DMXAA administration (Fig-
ures S3F and S3G). This result conclusively demonstrates that
STING activation results in activation of CD8+ T cells in an anti-
gen-specific manner.
STING Activation Enhances Survival of Leukemia-
Bearing Mice
To determine whether the powerful effect of STING activation on
T cell priming correlated with improved disease control, animals
with established C1498.SIY AML were treated with DMXAA or
vehicle, and survival was assessed. As shown in Figure 3A, a sin-
gle dose of DMXAA significantly prolonged survival of leukemia-
bearing mice compared to those treated with vehicle control.
In fact, 60% of DMXAA-treated mice survived long term.
Because SIY is an immunogenic model antigen, the ability of
DMXAA to control the progression of parental C1498 AML also
was tested. Here again, DMXAA-induced STING activation as
a single therapeutic maneuver significantly prolonged survival,
albeit to a lesser extent than in the C1498.SIY model (Figure 3B).
Survival following DMXAA or vehicle control treatment was
similarly poor in leukemia-bearing Tmem173/ mice, demon-
strating that the effect of DMXAA on disease control was STING
dependent (Figures 3C and 3D).
To investigate the extent to which host type I IFN signaling was
important for enhanced survival following STING activation,
wild-type and Ifnar/ mice were challenged with C1498 AML
cells and treated with DMXAA or vehicle control. Survival was
similar in vehicle control-treatedwild-type and Ifnar/mice (Fig-
ure 3E), as previously shown (Figure 1B). As expected, DMXAA
treatment led to a significant survival enhancement in wild-type
mice, but survival also was extended to some degree in
AML-bearing Ifnar/ mice that received DMXAA (Figure 3E).
Together, these data demonstrate that STING activation induces
both type I IFN-dependent and -independent effects, which
enhance leukemia-specific immunity and promote survival in
AML-bearing mice.
Finally, because DMXAA is a selective agonist of murine,
but not human, STING, the efficacy of a synthetic CDN STING
agonist capable of activating both mouse and human STING
was tested. This compound, dithio-(RP, RP)-[cyclic[A(2
0,50)
pA(30,50)p]] (ML RR-S2 CDA or simply CDA), has been shownCell Reports 15, 2357–2366, June 14, 2016 2359
Figure 2. DMXAA-Induced STING Activation Potentiates Leukemia-Specific CD8+ T Cell Responses
C57BL/6 mice received 106 C1498.SIY cells i.v. or remained leukemia-free. Mice were treated with 450 mg DMXAA or vehicle control i.v. (day 5), and cells were
harvested for analysis one week later (day 12).
(A–C) Splenic or bone marrow SIY-specific CD8+ T cells were analyzed following SIY/Kb pentamer staining by flow cytometry. Representative plots show SIY/Kb
pentamer staining (A). Numbers indicate frequency of SIY-specific CD8+ T cells. Frequency (left) and absolute number (right) of splenic SIY-specific CD8+ T cells
are shown (B). Frequency of bone marrow SIY-specific CD8+ T cells is shown (C).
(D and E) Spleen cells from indicated mice were re-stimulated in vitro with SIY peptide, and the production of IFN-g by CD8+ T cells was analyzed. Representative
plots demonstrating IFN-g production by CD8+ T cells are shown, and numbers indicate the frequency of IFN-g+ CD8+ T cells (D). Frequency (left) and absolute
number (right) of IFN-g+ CD8+ T cells in the indicated groups are shown (E).
(B, C, and E) Data shown are pooled from at least two independent experiments, each with three mice per group, and represented as mean ± SEM (*p < 0.05 or
**p < 0.01 for comparison of DMXAA- versus vehicle control-treated C1498.SIY-bearing mice).
2360 Cell Reports 15, 2357–2366, June 14, 2016
Figure 3. STING Activation Prolongs Survival in Mice with AML
C57BL/6 (A–F), Tmem173/ (C and D), or Ifnar/ (E) mice were challenged with 106 C1498.SIY (A, C, and F) or parental C1498 (B, D, and E) cells i.v. On day 5 (A,
C, and F) or on days 3 and 10 (B, D, and E), mice were treated with DMXAA (A–E) or CDA (F) versus vehicle control i.v., and survival was assessed. (A–F) Data
are pooled from two to three independent experiments each with three to five mice per group; ***p < 0.001 for comparison of survival between DMXAA- and
vehicle-treated C57BL/6 mice (A–E) or between CDA- and vehicle-treated C57BL/6 mice (F); ****p < 0.001 for comparison of survival between DMXAA- and
vehicle-treated Ifnar/ mice (E).to generate an anti-tumor T cell response and disease regres-
sion when administered intra-tumorally in solid tumor models
(Corrales et al., 2015). To assess whether CDA treatment also
would extend survival in animals with systemic AML, C57BL/6
mice were challenged with C1498.SIY cells i.v., followed
by CDA or PBS on day 5. As shown in Figure 3F, CDA-
treated leukemia-bearing mice survived significantly longer
than controls.
DMXAA Therapy Requires Adaptive Immunity and
Promotes Immunologic Memory against Native AML
Antigens
To examine the role of the adaptive immune system in regu-
lating the DMXAA effect on survival of AML-bearing mice,
C57BL/6 and Rag2/ mice (the latter of which lacks mature
B and T cells) were challenged with C1498 or C1498.SIY
cells, and they were treated with DMXAA or vehicle control. As
demonstrated previously, DMXAA treatment enhanced survival
of C57BL/6 mice following a systemic inoculation of C1498.SIY
(Figure 4A) or parental C1498 cells (Figure 4B), when compared
to vehicle control-treated animals. However, the survival ofleukemia-bearing Rag2/ mice was identical in DMXAA- and
control-treated mice (Figures 4A and 4B), indicating that the
therapeutic effect of STING activation in AML-bearing animals
requires adaptive immunity.
It was next determinedwhether functional memory was gener-
ated against native C1498-expressed antigens following DMXAA
treatment. C57BL/6 mice that survived a primary i.v. C1498.SIY
challenge after treatment with DMXAA received a subsequent
challenge with parental C1498 cells 100 days later. A second
group of C57BL/6 mice received a primary i.v. C1498 cell chal-
lenge simultaneously as a comparator cohort. DMXAA treatment
of leukemia-bearing mice promoted a remarkable survival
benefit following AML cell re-challenge, clearly demonstrating
that effective memory responses are generated against native
C1498 antigens following STING activation (Figure 4C).
STING Activation Is Effective in a Genetically
Engineered AML Model
To assess whether STING activation would be effective in a sec-
ond AML model, the Cbfb-MYH11/Mpl-induced mouse leuke-
mia model (CMM+) was utilized. This genetically engineeredCell Reports 15, 2357–2366, June 14, 2016 2361
Figure 4. DMXAA Therapy Requires Adaptive Immunity and Generates Effective Memory Responses to Naturally Expressed AML Antigens
(A andB) C57BL/6 orRag2/mice received 106C1498.SIY (A) or C1498 (B) cells i.v. On day 5 (A) or on days 3 and 10 (B)micewere treatedwith DMXAA or vehicle
control i.v., and survival was assessed (***p < 0.001 for survival in DMXAA- versus vehicle-treated C57BL/6 mice).
(C) DMXAA-treated survivors of a primary C1498.SIY cell challenge received 106 parental C1498 cells i.v. approximately 100 days following the initial C1498.SIY
cell inoculation. Naive C57BL/6mice inoculated with C1498 cells served as controls (****p < 0.0001 for survival in long-term C1498.SIY survivors versus leukemia-
naive mice following inoculation with C1498 cells).AML model mimics human inv(16) AML. Mice with established
CMM+ leukemia received DMXAA or vehicle control treatment
weekly. STING activation resulted in a significant decrease in
the frequency of AML cells in spleens of treated mice (Figures
5A and 5B), with a corresponding decrease in splenomegaly
(data not shown). These anti-tumor effects also translated into
extended survival of DMXAA-treated CMM+ mice compared to
controls (Figure 5C) and demonstrate that the effectiveness of
immunotherapy with STING agonists is not limited to a single
AML model.
DISCUSSION
The observation that AML failed to induce a host type I IFN
response is indicative of an impaired capacity of the innate
immune system to sense a disseminated leukemia, possibly
through lack of STING activation. The ability of leukemia cells
inoculated s.c., but not i.v., to induce type I IFN expression (Fig-
ure 1A), aswell as the finding that systemic AMLprogressed inde-
pendently of type I IFN signaling on host cells (Figure 1B), argues
that thedisseminatednatureof leukemiamaybe thecritical factor.
Precisely why systemic leukemia fails to activate type I IFN is not
known and is being actively explored in our laboratory. Regard-
less, systemic administration of a STING agonist stimulated
expression of type I IFN and other cytokines that may have
contributed to itseffectiveness.DMXAAdemonstrated impressive
therapeutic efficacy in two aggressive syngeneic AML models,
potently activated leukemia antigen-specific T cells, and induced
immunological memory against naturally expressed leukemia
antigens.2362 Cell Reports 15, 2357–2366, June 14, 2016The therapeutic effect of DMXAA was STING dependent and
partially required type I IFN responsiveness in host cells. The
latter finding is interesting, and it suggests that additional cyto-
kines, such as TNF-a, may be functioning downstream of
STING activation to promote anti-leukemia immunity. In fact,
DMXAA initially was shown to mediate cancer regression
through an effect on tumor vasculature, largely through TNF-a
(Joseph et al., 1999; Zhao et al., 2002). The extent to which
TNF-a and other cytokines are involved in the DMXAA effect
in leukemia-bearing mice is currently being explored. That
STING activation stimulates production of a variety of cytokines
aside from type I IFN argues that this approach might be supe-
rior to treatment with type I IFN alone, which has demonstrated
limited clinical efficacy in AML (Anguille et al., 2011; Smits et al.,
2013). Furthermore, STING activation is more effective in con-
trolling established leukemia than approaches targeting other
nucleic acid-sensing receptors, including Toll-like receptor 3
(TLR3) (data not shown) and TLR9 (Hossain et al., 2014).
Another important observation was the requirement for adaptive
immunity following STING activation, as DMXAA treatment was
completely ineffective when administered to leukemia-bearing
Rag2/ mice. This contrasts what has been reported in some
solid tumor models, in which a partial T cell-independent effect
of STING agonists has been described (Corrales et al., 2015).
The T cell-independent effect of STING activation in solid tu-
mors may be related to the well-known anti-angiogenic proper-
ties of IFN-b and vascular destructive effects of TNF-a
(Spaapen et al., 2014; Zhao et al., 2002), which are perhaps
more relevant in neo-vascularized solid cancers compared to
acute leukemia.
Figure 5. DMXAA Decreases Tumor Burden and Prolongs Survival in a Genetically Engineered AML Model
Mice were challenged i.v. with Cbfb-MYH11/Mpl+ (CMM+) AML cells on day 0 and treated with DMXAA or vehicle control on days 7 and 14.
(A and B) AML burden as measured by the frequency of GFP+ c-kit+ cells in the spleens of DMXAA or vehicle control-treated mice on day 17. (A) Representative
plots with numbers indicating frequency of GFP+ c-kit+ cells among total spleen cells are shown. (B) Quantified frequency of splenic AML cells is shown. Data in
(B) are pooled from two independent experiments, each with three to four mice per group, and represented as mean ± SEM (**p < 0.01).
(C) Survival ofCbfb-MYH11/Mpl+ AML-bearing animals following DMXAA or vehicle control treatment. Data in (C) are pooled from two independent experiments,
each with three to four mice per group (***p < 0.001).Several groups have reported recently that STING agonists,
administered directly into the tumor as single agents, or s.c.
with irradiated tumor cells, are capable of inducing potent immu-
nity against a variety of transplanted solid cancers (Corrales et al.,
2015; Fu et al., 2015). Locally administered STING agonists also
augment anti-tumor immune responses following radiation ther-
apy (Deng et al., 2014). Our recent work has indicated that a
unique immune evasion mechanism is active in AML in which
antigen-specific CD8+ T cells undergo abortive proliferation and
are rapidly deleted from leukemia-bearing animals (Zhang et al.,
2013). The ability of STING agonists to overcome this dense
Tcell-tolerant state that exists inAML-bearingmice is remarkable.
A potential limitation of this study is the use of transplantable
C1498 and CMM+ leukemia models, where disease induction
through i.v. inoculation likely fails to recapitulate several biolog-
ical aspects of AML. Investigating the role of STING pathway
activation in more physiologically relevant AML models will be
an important area of future study. Furthermore, given the broad
efficacy of localized STING therapy across solid tumor models,we speculate that systemic STING activation will be efficacious
in autochthonous AML models and also against other dissemi-
nated hematological malignancies.
Modified CDNs have been developed that bind both murine
and all human STING alleles, and, like DMXAA, they potently
induce activation of the STING axis. CDA, a lead CDN, has
shown potent anti-tumor activity in several studies (Corrales
et al., 2015; Fu et al., 2015). Systemic delivery of CDA to AML-
bearing mice in our study also was effective at improving survival
of AML-bearing animals, similar to DMXAA treatment. The maxi-
mally effective dose and schedule of the CDA compound, when
administered systemically, will require further study in order to
define its optimal effect in vivo.
Although STING activation appears to be broadly effective
as cancer immunotherapy, counter-regulatory immune evasion
pathways, including IFN-g-induced PD-L1 upregulation in the
tumor environment (Spranger et al., 2013; Fu et al., 2015),
enhanced production of the immunosuppressive indolamine-
2,3-dioxygenase (IDO) enzyme (Spranger et al., 2013), andCell Reports 15, 2357–2366, June 14, 2016 2363
the influx of regulatory T cells into the tumor environment
(Spranger et al., 2013) may limit its use as a single agent. Thus,
defining immune escape pathways that are activated following
STING agonist therapy and developing therapeutic combination
strategies to override them will be important to consider in future
studies.
As the development of STING agonists for use in humans
evolves, defining the efficacy and underlying mechanisms of ac-
tion in both solid and hematologic cancers will be crucial. The
focus of STING pathway agonists for clinical use has thus far
centered on their role as vaccine adjuvants and as cancer immu-
notherapeutic agents for treatment of solid tumors. However, our
results demonstrate similar impressive improvements in survival
and immune responses in pre-clinical AML models, and they
provide strong rationale for the clinical translation of STING
agonists as immune therapy for leukemia and possibly other
hematologic malignancies.
EXPERIMENTAL PROCEDURES
Mice and Leukemia Cell Lines
C57BL/6 (H-2b) mice, aged 6–12 weeks, were purchased from Taconic.
Tmem173/ and Ifnar/ mice have been reported previously (Ishikawa and
Barber, 2008;M€uller et al., 1994), and theywere provided by Y.X. Fu (University
of Chicago). IL-12 yellow fluorescent protein (YFP) reporter mice were
purchased from Jackson ImmunoResearch Laboratories. Rag2/ and 2C/
C57BL/6 mice were bred in our facility. All mice were maintained in a specific
pathogen-free environment. The C1498 cell line of C57BL/6 origin (H-2b) was
purchased from ATCC. C1498 has been classified as an AML but also has
NK-T cell properties (LaBelle and Truitt, 2002). C1498 cells transduced
to express the model SIY (SIYRYYGL) peptide antigen (C1498.SIY) were
generated in our laboratory as previously described (Zhang et al., 2009).
Real-Time qPCR Analysis
C57BL/6, Tmem173/, or Ifnar/ mice were treated with DMXAA or vehicle
control, and spleen cells were harvested 6 hr later. For the measurement of
cytokine expression in leukemia-bearing mice, 5 3 106 C1498 cells were in-
jected by i.v. or s.c. route. Spleen or lymph node cells, respectively, were har-
vested 72 hr later. All samples were re-suspended in Trizol (Life Technologies)
and total RNA was isolated via chloroform extraction. The cDNA was
synthesized using High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). The qPCR reactions were performed using TaqMan Gene
Expression Master Mix (A&B), and a 7300 Real Time PCR system (A&B) was
then performed for Ifnb, Tnfa, and Il6.
ELISA
C57BL/6 mice were treated with DMXAA or vehicle control and serum was
obtained 6 hr later. ELISA was performed for IFN-b, TNF-a, and IL-6 using
pre-coated plates (BioLegend) according to the manufacturer’s protocol.
AML Models
C1498 or C1498.SIY cells (106) were injected i.v. into the lateral tail vein of
recipient mice, and survival or immune responses were analyzed. To induce
localized C1498 tumors, 106 C1498 cells were inoculated s.c. in the lower
lateral abdominal wall. Tumor volume was measured two to three times
weekly, and animals were euthanized when the maximal tumor diameter
reached 20 mm or when tumor ulceration or other clinical signs of distress
developed. To generate the Cbfb-MYH11/Mpl-induced mouse leukemia
model (CMM+), polyinosinic-polycytidylic acid (poly(I:C)) was administered to
Cbfb+/56M/Mx1-Cre+ mice to induce expression of core-binding factor
b-smooth muscle myosin heavy chain(Kuo et al., 2006). Then 2 weeks later,
bone marrow cells were harvested and transduced with the retroviral MIG-
Mpl vector and GFP genes to generate a transplantable Cbfb-MYH11/Mpl+
mouse AML, as previously described (Hossain et al., 2014).2364 Cell Reports 15, 2357–2366, June 14, 2016In Vivo Administration of STING Agonists
DMXAA (Sigma-Aldrich) was dissolved in sterile 7.5% NaHCO3 and 450 mg
was injected i.v. on the day(s) indicated in each experiment. CDAwas provided
by Aduro Biotech and diluted in sterile PBS; 100 mg was injected i.v.
Pentamer Staining and Flow Cytometric Analysis
SIY/Kb pentamers were purchased from Proimmune. Spleen or bone marrow
cells from experimental animals were stained with SIY/Kb-PE pentamers ac-
cording to the manufacturer’s protocol, followed by anti-CD4–PerCP-Cy5.5
and anti-B220–PerCP-Cy5.5 antibodies (to exclude CD4+ T cells and B cells),
anti-CD8–FITC, and anti-Thy1.2-APC antibodies. Non-viable cells were
excluded from the analysis with a viability dye (Life Technologies). Flow cy-
tometry was performed on a Fortessa cytometer (BD Biosciences) with BD
FACSDiva software. Data analysis was performed with FlowJo software
(Tree Star) to identify the frequencies and absolute numbers of SIY-specific
CD8+ T cells.
Adoptive Transfer of 2C T Cells into Leukemia-Bearing Mice
The 2C CD8+ TCR Tg T cells, specific for the SIY antigen in the context of Kb,
were purified from spleens of 2C/C57BL/6 mice by positive selection using a
CD8 microbead kit, according to the manufacturer’s protocol (Miltenyi). Puri-
fied 2C T cells were labeled with CellTrace Violet (CTV) (Life Technologies)
according to the manufacturer’s protocol. CTV-labeled 2C T cells (106) were
injected into C57BL/6 mice i.v; 1 day later, mice received 106 C1498.SIY cells
i.v. DMXAA or vehicle was administered as indicated. Then 7 days later,
spleens were harvested and stained with anti-CD8, anti-Thy1.2, and anti-
1B2 antibodies (the 1B2monclonal antibody recognizes the 2C TCR), followed
by secondary labeling with streptavidin-PE. Flow cytometry analysis was then
performed.
Adoptive Co-transfer of OT-1 and 2C T Cells
OT-1 and 2C T cells were isolated from OT-1 (Thy1.1+) and 2C (Thy1.2+)
mice using a CD8 microbead kit (Miltenyi). Purified OT-1 and 2C T cells
were mixed at a 1:1 ratio, and 2 3 106 T cells (106 2C and 106 OT-1
T cells) were co-transferred into groups of C57BL/6 mice. Then 24 hr later,
half of the mice received C1498.SIY cells i.v., while the other half remained
leukemia free. DMXAA or vehicle was administered on day 5, and, 7 days
later, spleen cells from each group of mice were analyzed by flow cytometry
after cell surface staining with anti-CD8, anti-Thy1.2, anti-Thy1.1, and anti-
1B2 antibodies in order to identify the frequencies of OT-1 and 2C T cells
present.
Intracellular Cytokine Staining
Spleens were harvested from leukemia-bearing mice 5–7 days following the
administration of DMXAA or vehicle. Spleen cells (107) from individual mice
were plated in flat-bottomed 48-well tissue culture plates and stimulated
with medium supplemented with SIY peptide (500 nM) at 37C for 1 hr, fol-
lowed by 4 hr in the presence of 1 mg/ml GolgiPlug (BD Biosciences). Cells
were re-collected and stained with anti-CD8 and anti-1B2 antibodies (for 2C
transfer experiments) or anti-CD8 and anti-Thy1.2 antibodies (for analysis of
endogenous SIY-specific CD8+ T cell responses). After washing, cells were
fixed and permeabilized for 30 min at 4C (eBiosciences FoxP3 intracellular
staining kit) and stained overnight with anti-IFN-g-PE antibody. After washing,
cells were analyzed for IFN-g production by flow cytometry after gating on 2C
T cells (Thy1.2+CD8+1B2+ cells) or endogenous CD8+ T cells (Thy1.2+CD8+
cells).
Statistics
Student’s t tests, ANOVA with Bonferroni correction, Mann-Whitney, and
Kruskal-Wallis test were used for statistical analysis. For survival analysis, Ka-
plan-Meier curves were generated and log-rank test was used to compare sur-
vival between groups. Statistics were performed using GraphPrism software.
A p value of <0.05 was considered statistically significant.
Study Approval
Animal experimentation was carried out under a protocol approved by an Insti-
tutional Animal Care and Use Committee.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2016.05.023.
AUTHOR CONTRIBUTIONS
E.C. designed and executed experiments, analyzed data, and drafted the
manuscript. X.C. designed and executed experiments and reviewed the
manuscript. L.C. assisted E.C. in experimental design and execution. T.W.D.
provided the CDA compound and intellectual guidance and reviewed the
manuscript. D.E.K., M.K., and P.D. designed experiments and reviewed the
manuscript. J.K. designed experiments, analyzed data, and drafted and re-
viewed the manuscript.
ACKNOWLEDGMENTS
This work was supported by R01 CA166770 and a University of Chicago Insti-
tute for Translational Medicine award (to J.K.). E.C. was funded by T32
CA009566-27 and NIH/National Institute of General Medical Sciences
(NIGMS) Clinical Therapeutics Training Grant T32GM007019. L.C. was funded
by a Cancer Research Institute Irvington Postdoctoral Fellowship. D.E.K. was
funded by the Immunology Training Grant at the University of Chicago (T32
AI007090). T.W.D. is a paid employee of Aduro Biotech, holds stock in the
company, and may be an inventor on patent applications that apply to the
CDN molecules described in the manuscript.
Received: November 16, 2015
Revised: March 21, 2016
Accepted: May 4, 2016
Published: June 2, 2016
REFERENCES
Anguille, S., Lion, E., Willemen, Y., Van Tendeloo, V.F., Berneman, Z.N., and
Smits, E.L. (2011). Interferon-a in acute myeloid leukemia: an old drug revis-
ited. Leukemia 25, 739–748.
Chen, H., Sun, H., You, F., Sun, W., Zhou, X., Chen, L., Yang, J., Wang, Y.,
Tang, H., Guan, Y., et al. (2011). Activation of STAT6 by STING is critical for
antiviral innate immunity. Cell 147, 436–446.
Corrales, L., Glickman, L.H., McWhirter, S.M., Kanne, D.B., Sivick, K.E.,
Katibah, G.E., Woo, S.R., Lemmens, E., Banda, T., Leong, J.J., et al.
(2015). Direct Activation of STING in the Tumor Microenvironment Leads
to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 11,
1018–1030.
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.D.,
Mauceri, H., Beckett, M., Darga, T., et al. (2014). STING-Dependent
Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-
Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 41,
843–852.
Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Arch-
ambault, J.M., Lee, H., Arthur, C.D., White, J.M., Kalinke, U., et al. (2011).
Type I interferon is selectively required by dendritic cells for immune rejection
of tumors. J. Exp. Med. 208, 1989–2003.
Dunn, G.P., Bruce, A.T., Sheehan, K.C., Shankaran, V., Uppaluri, R., Bui, J.D.,
Diamond, M.S., Koebel, C.M., Arthur, C., White, J.M., and Schreiber, R.D.
(2005). A critical function for type I interferons in cancer immunoediting. Nat.
Immunol. 6, 722–729.
Fu, J., Kanne, D.B., Leong, M., Glickman, L.H., McWhirter, S.M., Lemmens, E.,
Mechette, K., Leong, J.J., Lauer, P., Liu, W., et al. (2015). STING agonist
formulated cancer vaccines can cure established tumors resistant to PD-1
blockade. Sci. Transl. Med. 7, 283ra52.
Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M.,
and Gajewski, T.F. (2011). Host type I IFN signals are required for antitumorCD8+ T cell responses through CD8alpha+ dendritic cells. J. Exp. Med. 208,
2005–2016.
Gajewski, T.F. (2007). Failure at the effector phase: immune barriers at the
level of the melanoma tumor microenvironment. Clin. Cancer Res. 13, 5256–
5261.
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-
Page`s, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006). Type,
density, and location of immune cells within human colorectal tumors predict
clinical outcome. Science 313, 1960–1964.
Hossain, D.M., Dos Santos, C., Zhang, Q., Kozlowska, A., Liu, H., Gao, C.,
Moreira, D., Swiderski, P., Jozwiak, A., Kline, J., et al. (2014). Leukemia cell-
targeted STAT3 silencing and TLR9 triggering generate systemic antitumor
immunity. Blood 123, 15–25.
Hwang, W.T., Adams, S.F., Tahirovic, E., Hagemann, I.S., and Coukos, G.
(2012). Prognostic significance of tumor-infiltrating T cells in ovarian cancer:
a meta-analysis. Gynecol. Oncol. 124, 192–198.
Ishikawa, H., and Barber, G.N. (2008). STING is an endoplasmic reticulum
adaptor that facilitates innate immune signalling. Nature 455, 674–678.
Ishikawa, H., Ma, Z., and Barber, G.N. (2009). STING regulates intracellular
DNA-mediated, type I interferon-dependent innate immunity. Nature 461,
788–792.
Joseph, W.R., Cao, Z., Mountjoy, K.G., Marshall, E.S., Baguley, B.C., and
Ching, L.M. (1999). Stimulation of tumors to synthesize tumor necrosis
factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel
approach to cancer therapy. Cancer Res. 59, 633–638.
Kuo, Y.H., Landrette, S.F., Heilman, S.A., Perrat, P.N., Garrett, L., Liu, P.P., Le
Beau, M.M., Kogan, S.C., and Castilla, L.H. (2006). Cbf beta-SMMHC induces
distinct abnormal myeloid progenitors able to develop acute myeloid leuke-
mia. Cancer Cell 9, 57–68.
LaBelle, J.L., and Truitt, R.L. (2002). Characterization of a murine NKT cell
tumor previously described as an acute myelogenous leukemia. Leuk.
Lymphoma 43, 1637–1644.
Mahmoud, S.M., Paish, E.C., Powe, D.G., Macmillan, R.D., Grainge, M.J.,
Lee, A.H., Ellis, I.O., and Green, A.R. (2011). Tumor-infiltrating CD8+ lym-
phocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29,
1949–1955.
Montoya, M., Schiavoni, G., Mattei, F., Gresser, I., Belardelli, F., Borrow,
P., and Tough, D.F. (2002). Type I interferons produced by dendritic cells
promote their phenotypic and functional activation. Blood 99, 3263–
3271.
M€uller, U., Steinhoff, U., Reis, L.F., Hemmi, S., Pavlovic, J., Zinkernagel, R.M.,
and Aguet, M. (1994). Functional role of type I and type II interferons in antiviral
defense. Science 264, 1918–1921.
Ohminami, H., Yasukawa, M., and Fujita, S. (2000). HLA class I-restricted lysis
of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1
peptide. Blood 95, 286–293.
Page`s, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R.,
Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005). Effector
memory T cells, early metastasis, and survival in colorectal cancer. N. Engl.
J. Med. 353, 2654–2666.
Smits, E.L., Anguille, S., and Berneman, Z.N. (2013). Interferon a may
be back on track to treat acute myeloid leukemia. OncoImmunology 2,
e23619.
Spaapen, R.M., Leung, M.Y., Fuertes, M.B., Kline, J.P., Zhang, L., Zheng, Y.,
Fu, Y.X., Luo, X., Cohen, K.S., and Gajewski, T.F. (2014). Therapeutic activity
of high-dose intratumoral IFN-b requires direct effect on the tumor vascula-
ture. J. Immunol. 193, 4254–4260.
Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., and Ga-
jewski, T.F. (2013). Up-regulation of PD-L1, IDO, and T(regs) in the melanoma
tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5,
200ra116.Cell Reports 15, 2357–2366, June 14, 2016 2365
Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z.J. (2013). Cyclic GMP-AMP syn-
thase is a cytosolic DNA sensor that activates the type I interferon pathway.
Science 339, 786–791.
Woo, S.R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung,
M.Y., Duggan, R., Wang, Y., Barber, G.N., Fitzgerald, K.A., et al. (2014).
STING-dependent cytosolic DNA sensing mediates innate immune recogni-
tion of immunogenic tumors. Immunity 41, 830–842.
Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., and Chen, Z.J. (2013). Cyclic
GMP-AMP is an endogenous second messenger in innate immune signaling
by cytosolic DNA. Science 339, 826–830.2366 Cell Reports 15, 2357–2366, June 14, 2016Zhang, L., Gajewski, T.F., and Kline, J. (2009). PD-1/PD-L1 interactions inhibit
antitumor immune responses in a murine acute myeloid leukemia model.
Blood 114, 1545–1552.
Zhang, L., Chen, X., Liu, X., Kline, D.E., Teague, R.M., Gajewski, T.F., and
Kline, J. (2013). CD40 ligation reverses T cell tolerance in acute myeloid leuke-
mia. J. Clin. Invest. 123, 1999–2010.
Zhao, L., Ching, L.M., Kestell, P., and Baguley, B.C. (2002). The antitumour
activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1
knockout mice. Br. J. Cancer 87, 465–470.
